These pathways involve changes in the gene expression of known cell-cycle inhibitors or activators, including the CDK (cyclin-dependent kinase) inhibitor p21CIP1 and p16INK4, a component of retinoblastoma (RB) tumor suppressor signalling cascades [23,24]. The gene discussed is CDKN2A; the disease is neoplasm.